Doxorubicin enhances curcumin's cytotoxicity in human prostate cancer cells in vitro by enhancing its cellular uptake by Klippstein, Rebecca et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.ijpharm.2016.08.003
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Klippstein, R., Bansal, S. S., & Al-Jamal, K. T. (2016). Doxorubicin enhances curcumin's cytotoxicity in human
prostate cancer cells in vitro by enhancing its cellular uptake. INTERNATIONAL JOURNAL OF
PHARMACEUTICS, 514(1), 169-175. DOI: 10.1016/j.ijpharm.2016.08.003
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 15. Dec. 2017
1 
 
Doxorubicin Enhances Curcumin’s Cytotoxicity in Human Prostate Cancer Cells In Vitro 
by Enhancing Its Cellular Uptake 
 
 
Rebecca Klippstein, Sukhvinder S Bansal and Khuloud T. Al-Jamal*  
 
 
Dr. R. Klippstein, Dr. S. Bansal, Dr. K.T. Al-Jamal 
150 Stamford Street,  
Institute of Pharmaceutical Science 
King's College London 
Franklin-Wilkins Building 
150 Stamford Street 
London SE1 9NH, UK 
E-mail: khuloud.al-jamal@kcl.ac.uk 
 
 
* Corresponding author 
 
Keywords: tumor, oil-core, combinatory therapy, anticancer, apoptosis 
 
 
 
 
 
 
 
 
 
 
2 
 
Graphical abstract  
 
Abstract 
Doxorubicin (DOX) is a widely used drug in cancer treatment. Despite its popularity, it 
suffers from systemic side effects and susceptibility to drug resistance. Curcumin (CURC), 
on the other hand, is a drug that recently gained popularity due to its wide range of biological 
activities, including anti-inflammatory and anti-cancer activities. Limitations to its clinical 
translation include its poor water solubility and the need for administration of high doses. 
Combinatory anti-cancer therapy has been proposed as a common approach to overcome one 
or more of these challenges. In this work, we propose a combinatory DOX and CURC anti-
cancer therapy of prostate cancer cells in vitro. DOX and CURC were administered in the 
free drug and nanocapsule form, respectively. Cell size and complexity, cytotoxicity and 
apoptosis were studied by flow cytometry, MTT assay and sub-G1 quantification, 
respectively. Cellular uptake of CURC nanocapsules (CURC NCs) was quantified with by 
fluorescence microscopy and high-performance liquid chromatography fluorescence 
DOX
CURC NCs
Combination treatment
+ uptake + cytotoxicity + apoptosis
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detection. Results showed that in vitro treatment with CURC NCs in the presence of 
subtherapeutic concentrations of DOX, led to significant increase in prostate cancer cells 
(PC3) apoptosis and death. This was likely due to significantly enhanced CURC uptake by 
the cells. The study presents a good rationale for pursuing combinatory CURC/DOX therapy   
in pre-clinical tumor animal models in the near future.   
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1. Introduction 
Cancer treatment options can be limited due to multidrug resistance and side effects. 
Recently, combination chemotherapy of multiple anticancer drugs has been extensively 
developed for overcoming these major pitfalls (Li et al., 2014).  The combinational anti-
cancer therapy of doxorubicin (DOX) and curcumin (CURC) represents an attractive strategy 
over single drug treatment to maximize the therapeutic response. DOX is a broad-spectrum 
chemo-therapeutic agent widely used for the treatment of several cancers including breast, 
ovary, cervix and prostate as reviewed recently (Tacar et al., 2013). Its effectiveness can be 
limited due to its high toxicity and side effects, including myelosuppression, alopecia, acute 
nausea, vomiting, stomatitis, cumulative cardiotoxicity (Hortobagyi, 1997), and multidrug 
resistance resulting, after repeated administration (Shen et al., 2008). Interestingly, a phase II 
trial showed that liposomal doxorubicin led to only modest anticancer activity for the 
treatment of hormone-refractory prostate cancer and it was suggested to include this agent in 
combination chemotherapy (Harris et al., 2002). In clinic, DOX has been used in multi-drug 
regimens with other anti-cancer agents, such as cyclophosphamide, 5-fluorouracil, docetaxel, 
vinblastine, and bleomycin (Hernandez and Perez, 1996; Itoh et al., 2000; Martin et al., 2003) 
Recent studies have reported that curcumin (CURC) can reduce DOX’s adverse reactions 
(Sadzuka et al., 2012).  
CURC has been reported in many studies to delay tumor growth via modulating different 
signalling pathways. Its limitations include poor water solubility and low potency, requiring 
administration of high CURC doses, in a solubilized drug form (Anand et al., 2007). We have 
recently reported the preparation of CURC NCs and confirmed their therapeutic efficacy in 
colon-bearing mice, following intravenous administration (Klippstein et al., 2015).  
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In this study, we propose a combinatory anticancer approach with free form and 
nanoformulation of DOX and curcumin, respectively. We hypothesize that co-treatment of 
human prostate cancer cells with CURC NCs and subtherapeutic doses of DOX can improve 
CURC’s uptake in cells improving its therapeutic efficacy. In vitro cellular uptake and drug 
quantification studies, followed by cytotoxicity and apoptotic assays were carried out to test 
our hypothesis.  
2. Material and Methods 
2.1 Material 
75/25 DL-lactide/glycolide conjugate (PLGA), Mw ≈ 18000, was a gift from Purac 
Biomaterials. CURC was purchased from Santa Cruz Biotechnology (UK). Snake Skin 
dialysis tubing (MWCO 10,000 Da) was purchased from Thermo-fisher (USA). Soybean 
lecithin (Epikuron 140 V) was a kind gift from Cargill Pharmaceuticals. Castor oil, Tween® 
80, acetone and absolute ethanol were obtained from Sigma-Aldrich (UK). RPMI-1640 
media, foetal bovine serum (FBS), penicillin/streptomycin, trypsin/EDTA, and phosphate 
buffered saline (PBS) were obtained from Gibco, Invitrogen (UK).  
List of chemical compounds 
PLGA (PubChem CID: 23111554); Soybean lecithin (PubChem CID: 57369748); CURC 
(PubChem CID: 969516); castor oil (PubChem CID: 14030006); Tween® 80 (PubChem 
CID: 5281955); ethanol (PubChem CID: 702); acetone (PubChem CID: 120).  
2.2 Cell Culture 
The human prostate carcinoma cells DU145 (ATCC
®
 HTB-81
™
) and PC3, kindly provided 
by Dr. M. Japon; Department of Endocrine Tumorigenesis and Hormonal Regulation of 
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Cancer, Biomedicine Institute of Seville, IBIS, CSIC-University of Seville, Spain, were 
cultured in Advanced RPMI media supplemented with 10% FBS, 50 U mL
−1
 penicillin, 50 μg 
mL
−1
 streptomycin, 1% l-glutamine, at 37 °C in 5% CO. Cells were routinely grown in 75 
cm
2
 canted-neck tissue culture flasks and passaged twice a week using Trypsin/EDTA at 80% 
confluency. 
2.3 Formulation of the NCs 
CURC NCs were prepared using the nanoprecipitation technique as described in one of our 
previous studies (Klippstein et al., 2015).  Briefly, CURC (5 mg), soybean lecithin (25 mg), 
and PLGA polymer (25 mg), were mixed at 1:2:0.1 molar ratio with 300 µL of castor oil 
dissolved in 5 mL of acetone/ethanol (60:40 v/v) mixture. This organic phase was added 
dropwise into the aqueous phase (10 mL) containing Tween® 80 (0.2%) as a hydrophilic 
surfactant; the mixture was maintained under magnetic stirring in the chemical hood for 30 
min to allow solvent to diffuse and form NCs. Organic solvents were then eliminated by 
evaporation under reduced pressure using a Buchi rotavap. The final volume of the colloidal 
suspension was adjusted to 10 mL.  
2.4 Uptake Studies In Vitro by Flow Cytometry 
Cells were seeded at a density of 5 × 10
4
 in 24-well plates, allowed to attach overnight and 
then treated with 20 µM of CURC NCs and 1 µM of DOX. After treatment, the cells were 
washed twice with PBS, trypsinized and centrifuged at 1500 rpm for 5 min and the cell pellet 
was resuspended in 250 μL of PBS. The internalization of CURC and DOX was studied on 
10,000 gated cells by detecting the fluorescence using FL2 channel detector and BD FACS 
Calibur flow cytometer (BD Biosciences). The measurements were done in triplicate and 
presented as mean ± SD. 
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2.5 Uptake Studies In Vitro by Confocal Laser Scanning Microscopy 
PC-3 cells were seeded onto glass coverslips at a density of 25 K cells per a well of a 24-well 
plates in RPMI media overnight. Cells were then incubated with 0.5 mL of 20 µM CURC 
NCs or 1 µM DOX or the combination for 4 h. At the end of incubation period, cell were 
rinsed, fixed (200 μL of 4% PFA for 15 min at RT) and subsequently counterstained with 
DAPI. Coverslips were mounted on glass slides using VectaShield mounting media. CURC 
NCs uptake was represented by the green signals, while DOX was represented by red signals 
and nuclei were detected in blue. Confocal images were captured using a Nikon Eclipse Ti 
inverted microscope, Nikon, Tokyo, Japan, using an objective lens 20×/0.75NA 505 nm 
output filter, and a Plan-Neofluar 10 lens. 
2.6 Quantitative Determination of Curcumin Uptake In Vitro by HPLC-FLd 
CURC uptake was quantified using a high-performance liquid chromatography fluorescence 
detection (HPLC-FLd) analytical method. Method validation has been reported in our 
previous study (Klippstein et al., 2015). Approximately 5x10
5 
PC3 cells were treated in a 6-
well plate with 1 µM DOX, 20 or 40 µM of CURC NCs or the combination for 4 h and 6 h. 
Cells were transferred into 15 mL test tubes and vortex-mixed for 20 s. One millilitre of 1X 
PBS was added and samples were homogenized using an ULTRA-TURRAX T18 
Homogenizer (IKA, GE). After the tissue was completely homogenized, 2 mL of the 
extraction solvent consisting of 98% acetonitrile and 2% TFA (v/v) was added and were left 
under agitation overnight. Samples were then centrifuged at 3000× g for 5 min at 4 °C and 1 
mL of the supernatant was transferred to a clean glass tube. The extraction was repeated 
twice with 1 mL of extraction solvent, and the pooled supernatants were concentrated using a 
centrifugal evaporator Genevac EZ2 (Genevac Ltd, UK) at low heat setting (40 °C). The 
content was transferred to an injection sample vial, and 50 μL was injected into the HPLC-
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FLd system (Agilent Technologies) using a Phenomenex C18 column (150 × 2.1 mm, 3.6 
μm) and a flow rate of 0.2 mL min. The mobile phase consisted of A: 0.1% TFA in H2O: 
acetonitrile (90:10) (v/v) and B: 0.1% TFA in H2O: acetonitrile (10:90) (v/v). The elution 
gradient was 10%–90% B in 30 min. Fluorescence detection, excitation 345 and emission 
530 nm. For HPLC-FLd analysis, CURC working solutions were prepared by dilution of the 
stock solution with the mobile phase reaching final concentrations of 1.0, 2.0, 4.0, and 8.0 μg 
mL −1. Peak areas were plotted against CURC concentrations. The linearity of the detector 
was determined over the concentration of CURC and a standard curve was calculated by 
linear regression.  
2.7 In Vitro Cytotoxicity Studies  
PC-3 cells were seeded in 96-well plates and incubated with different concentrations of NCs 
or DOX (200 μL final volume) in complete media for 24 and 72 h. Cytotoxicity was 
examined by MTT assay. Briefly, at the end of the incubation period, media was removed 
and replaced with 120 μL of MTT solution at a final concentration of 0.5 mg mL−1. Cells 
were incubated for 3 h at 37 °C and 5% CO2. At the end of the incubation, formazan was 
dissolved in 200 μL of DMSO and the plate was read at 570 nm in a FLUO star OPTIMA 
plate reader (BMG Labtech).  Results were expressed as the percentage cell survival (mean ± 
SD) and calculated using the following equation: % Cell survival = (A570 nm of treated 
cells/A570 nm of untreated control cells) × 100. 
2.8 Assessment of Late Apoptosis by Sub-G1 Quantification 
Late apoptosis induced by CURC NCs and/or DOX were measured by quantifying the 
fraction of cells displaying reduced amount of DNA, named sub-G1 population. PC-3 and 
DU-145 cells were seeded at 5 × 10
4
 cells per well in 24-well plates and incubated overnight 
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at 37 °C with 5% CO2. Cells were then treated with 20 µM and 40 µM of CURC NCs. At the 
end of treatment period, floating cells were collected and adherent cells were trypsinized and 
transferred into BD flow cytometer tubes. After centrifugation at 800 × g for 5 min and 
washing in PBS, cells were re-suspended in 100 μL of PBS and 900 μL of 70% cold ethanol 
for fixation and stored overnight at 4 °C. Fixed cells were then centrifuged, washed in PBS, 
and treated in a mix of 250 μL of PBS and 250 μL of DNA extraction buffer (Na2HPO4 190 × 
10
−3
 m, Citric Acid 4 × 10
−3
 m, pH 7.8) for 10 min at 37 °C. Samples were then centrifuged 
and re-suspended in 50 μL of RNase in PBS (100 μg mL−1) before being stained for 30 min at 
37 °C in the dark with 400 μL of propidium iodide (PI) solution (40 μg mL−1 of PI in PBS). 
PI fluorescence was analyzed by flow cytometry using a BD FACS Calibur flow cytometer 
obtained from BD Bioscience (US). Finally, 10,000 cells were gated and fluorescence of Sub-
G1 population was analyzed in triplicates for each condition using the FL2 detector. Results 
were expressed as average ± SD (n = 3). 
 
3. Results 
3.1 Physico-chemical Characterization of CURC NCs and CURC loading.  
CURC NCs formulation and physico-chemical characterization have been described in our 
previous report (Klippstein et al., 2015). In brief, CURC NCs exhibited hydrodynamic 
diameter and zeta-potential of 150.5 ± 4.7 nm and -37.2 ± xx mV, respectively.  Percentage 
encapsulation efficiency and drug loading were  92.3% ± 1.6 and 18.4% + 0.3, respectively.  
3.2 Morphological studies of PC3 cells by flow cytometry 
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The morphology of PC3 cells was evaluated after treatment with DOX, CURC NCs and the 
combination. The cells were treated for 4 h and size (FSC) and granularity (SSC) were 
measured by flow cytometry. Cells treated with the combination became less granular and 
significantly smaller in size compared to cells treated with either DOX or NCs (Figure 1). 
This morphology is typically associated with dying cells suggesting an additive effect of both 
drugs.  
 
 
 
 
 
 
 
DOX 1 µM CURC 20 µM CURC NC 20 µM
DOX 1 µM + NC DOX 1µM + CURC NC 20 µM
CURC NC
DOX
DOX + CURC NC
SS
C
FSC FSC
C
o
u
n
t
Figure 1. Cell size and granularity of PC3 prostate cancer cells, after intracellular 
uptake of doxorubicin (DOX), empty NC (NC), curcumin-loaded NC (CURC NC) or 
their combinations. Changes in cell size (FSC detector) and granularity (SSC detector) were 
assessed after 4 h of incubation by flow cytometry. The combination of DOX and CURC NC 
but not any of the individual treatments lead to reduction in cell size, reflecting enhanced 
overall cytotoxicity of the combinatory treatment.   
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3.3 Intracellular uptake studies of DOX, CURC NCs and the combination in PC3 human 
prostate cancer cells in vitro.  
The intracellular uptake of intrinsically fluorescence CURC and DOX was studied in PC3 
cells by fluorescence microscopy, flow cytometry and HPLC-FLd. PC3 cells were treated 
with 1 µM DOX and 20 or 40 µM of CURC NCs for 4 h. The cellular uptake and distribution 
of DOX and CURC was investigated by fluorescence microscopy (Figure 2A). As DOX and 
CURC exhibit intrinsic green and red fluorescence, respectively, no additional probe 
labelling, except DAPI to stain the nuclei, was required for imaging. At 4 h, DOX primarily 
located in the nuclei; whereas CURC NCs were detected in the cytoplasm.  This can be 
verified by the fact that the nuclei counterstained with DAPI (blue color) were less evident 
for DOX treatments than for CURC NCs. The uptake of the combination treatment was 
studied by flow cytometry (Figure 2B). Cells that appeared smaller in size and with lower 
granularity were gated separately (gate 2), showing two fluorescence peaks matching CURC 
and DOX peaks. In contrast, cells that appeared larger in size and with higher granularity 
(gate 1) only showed one fluorescence peak corresponding to DOX. This result indicates that 
DOX is taken up by most of the cells, within 4 h treatment, and that only those that have 
taken up CURC NCs as well as DOX, start shrinking as a consequence of cell-death. 
Additionally, a higher uptake of CURC NCs is detected when cells were co-treated with 
DOX. This suggests that DOX helps NC internalization into cells.  
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Figure 2. Intracellular uptake of CURC NC, in presence or absence of DOX, in PC3 
human prostate cancer cells in vitro. (A) Cellular uptake of DOX (red fluorescence) and 
CURC NC (green fluorescence) was assessed by fluorescence microscopy after 4 h of 
incubation. Nuclei were counterstained with DAPI (blue). The scale bar corresponds to 25 µm. 
(B) Dot plots showing PC3 cells after 4 h of incubation with the different treatments. 
Histograms display the fluorescence signals detected from each cell population. Cells treated 
with CURC NC or DOX show individual cell population; with low and high FL2 intensity 
signals, indicative of CURC and DOX uptake, respectively. Cells treated with the combinatory 
treatment show two overlapping populations; cells in population 1 are larger in size and are 
positive for DOX signals (high FL2 intensity). Cells in population 2 are smaller in size, 
reflecting cytotoxicity, and are positive for CURC signals (low FL2 intensity).  
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To confirm this observation, the uptake of CURC NCs in PC3 cells, in absence or presence of 
DOX, was quantified. Cells were treated with DOX, CURC NCs or the combination for 4 h 
and 6 h. The cells were then lysed and fluorescence intensity was quantified by HPLC-FLd. 
Commercially available CURC consists of curcumin, demetoxycurcumin, and di-
demethoxycurcumin. These were observed at retention times of 21.2, 21.8, and 22.5 min 
(Figure S1).  CURC was quantified using a calibration curve calculated by linear regression 
(Figure S1). Interestingly, CURC fluorescence detected for the combination treatment DOX 
(1 µM) and CURC NCs (40 µM) was higher than the equivalent doses of CURC NCs alone 
(Figure 3C). This confirms our hypothesis that an enhancement in CURC NCs uptake has 
occurred when cells were co-treated with DOX.  
 
Figure 3. Quantification of the intracellular uptake of CURC NCs in PC3 human 
prostate cancer cells in vitro by HPLC-FLd. Cells were quantified for intracellular CURC 
content following 4 h or 6 h of incubation by HPLC-FLd, using a C18 column, 
excitation/emission wavelengths of 345/530 nm and 0.1% TFA in H2O: acetonitrile mobile 
phase.  
3.4 CURC NCs potentiates DOX-induced cytotoxicity of human prostate cancer cells in 
vitro. 
The cytotoxic effect of DOX, CURC NCs and the combination was screened in PC3 cells in 
vitro. Light microscopy images showed no morphological changes when cells were treated 
0
5
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U
C
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with DOX or CURC NC for 24 h. As expected, cells treated with the combination appeared 
more round and smaller in size (Figure 4A). Cell viability was assessed with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay at 0.1 or 1 µM of DOX, 
20 or 40 µM of CURC NC, or the combinations. An enhanced cytotoxicity was observed 
after 72 h incubation with the combination treatments at both 0.1 and 1 µM DOX and 20 and 
40 µM of CURC NCs concentrations. The difference was moderate in the case of 0.1 µM 
DOX but increased dramatically in case of 1 µM of DOX (Figure 4B).  
 
 
 
*
**
***
***
***
**
Control NC
CURC NC 20 µM DOX 1µM
DOX 1µM + 
CURC NC 20µM
A B
CURC NC (µM)
DOX (µM)
- - 20         20      40     40       60      60      
- 0.1        - 0.1      - 0.1       - 0.1 
- - 20         20      40     40       60      60      
- 1       - 1         - 1          - 1 
CURC NC (µM)
DOX (µM)
Figure 4. Cytotoxicity studies of CURC NC, in presence or absence of DOX, in PC3 
human prostate cancer cells in vitro. (A) Microscopic examination of PC3 cells after 
treatment with DOX, CURC NC or combinatory treatment, for 24 h. Cell rounding and 
reduction in cell number was observed for cells treated with the combinatory treatment. The 
scale bar corresponds to 50 µm. (B) PC3 cells were incubated with DOX (0.1 or 1 µM), 
CURC NC (20, 40 or 60 µM) or the combinations for 72 h. Cell viability was determined by 
MTT assay. Values are expressed as mean ± SD (n = 3). * P < 0.05, ** P < 0.01, *** P < 
0.001 (one-way ANOVA test). Asterisks correspond to statistically significant differences 
between particular groups. 
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3.5 CURC-loaded NCs and DOX combinations enhanced the apoptosis in human prostate 
cancer cells.  
Sub-G1 analysis allows quantification of hypodiploid cell percentage entering into the 
apoptotic SubG1 phase. PC3 cells and DU145 cells were analyzed by FACS and results 
showed that DOX combined with CURC NCs treatments increased SubG1 population of cells 
at 24 h. Interestingly, the combination treatment of 1 µM DOX and 20 µM CURC NCs 
showed a 20% significant increase in the subG1 phase. Similar values were observed with 
higher concentrations of DOX and CURC NCs, confirming that 1 µM DOX and 20 µM NCs 
seem to be the most effective for cell killing. 
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14.99 %
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Figure 5. Percentage SubG1 cell population in PC3 human prostate cancer cells 
following combinatory treatments in vitro. (A) Representative histograms of SubG1 
quantification in PC3 cells incubated with DOX, CURC, CURC NC or the combinatory 
treatments, following 24 h treatment. (B) Percentage SubG1 quantification in PC3 (top) and 
DU145 cells (bottom) after 24 h treatment. SubG1 was quantified by using PI staining 
method. The combinatory treatment significantly increased the % of SubG1, compared to 
individual DOX or CURC treatments. Values are expressed as mean ± SD (n = 3). 
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4. Discussion 
DOX is one of the most widely used therapeutic drugs in cancer. Unfortunately, many tumor 
cells are inherently resistant to DOX or can acquire chemo-resistance shortly after 
commencing the therapy, leading inevitably to treatment failure (Notarbartolo et al., 2005). 
An effective strategy to tackle chemo-resistance is the identification and evaluation of drug 
combinations (Misra and Sahoo, 2011). Previous studies have demonstrated that CURC may 
interfere with NF-kB activation and increase tumor cell response to different NF-kB 
activating anticancer drugs, including DOX (Hour et al., 2002; Notarbartolo et al., 2005). Its 
major roadblocks for clinical translation in cancer therapy are however related to its poor 
water solubility, poor pharmacokinetics and limited bioavailability (Kunnumakkara et al., 
2008). In a previous report, we have shown that long blood-circulating CURC-loaded oil-
cored polymeric NCs delivered doses of CURC to solid tumors, after systemic administration 
in vivo (Klippstein et al., 2015), that were sufficient to result in tumor (colon) growth delay. 
In an attempt to improve the therapeutic efficacy of CURC, a combinatory anti-cancer 
therapy approach is proposed here by using low doses of DOX (in free form) and s form of 
CURC. The rationale for using free DOX here was that the free drug can enter the cell very 
quickly by passive diffusion (Soininen et al., 2016) which then facilitates entry of CURC 
NCs that is otherwise only effective at high doses. This combination therapy approach may 
offer some advantages over other nanoformulations co-encapsulating both drugs in the same 
carrier. Their rationale was that co-encapsulation of DOX and CURC in one carrier could 
lead to an interaction of both drugs and may result in an incomplete release (Zhao et al., 
2015). In addition, other reports have demonstrated a reduction in DOX cytotoxicity when 
encapsulated in a nanoformulation (Gonzalez-Fajardo et al., 2016). 
It is unclear why co-treatment with DOX improves the therapeutic efficacy overall. The 
intracellular uptake of DOX, CURC NCs and the mixture was studied by fluorescence 
17 
 
microscopy, flow cytometry and HPLC-FLd. Interestingly, fluorescence microscopy, flow 
cytometry and HPLC-FLd all showed complementary results that best results were achieved 
when cells were treated with the mixture of 1 µM DOX and 40 µM CURC NCs at 6 h and 
suggest that co-treatment with DOX led to an increase in intracellular uptake of CURC NCs.  
There was a clear reduction in cell size, reflecting an enhanced toxicity compared to single 
treatments. Low concentrations of DOX can result in loss of membrane integrity (Eom et al., 
2005) facilitating entry of the rather normally “slow-entering” NCs. Another possible 
explanation, which cannot be excluded here, is that CURC could help retaining DOX in the 
cell nucleus and inhibit its efflux, as supported by others (Misra and Sahoo, 2011). 
5. Conclusion 
This work reports that combinatory treatment of DOX and CURC NCs can improve the 
outcome of anti-cancer therapy in prostate cancer in vitro. While the exact mechanism is still 
unknown, we confirmed that the uptake of CURC NCs in cancer cells significantly improved 
upon co-treatment with DOX, at sub-therapeutic concentrations of the latter. Combination 
treatments enhanced significantly cell viability compared to single treatments, assessed by 
cytotoxicity and apoptosis studies in prostate cancer cells in vitro, particularly at 1 µM DOX 
and 20 µM CURC NCs combinatory treatment. Future studies will focus on testing 
therapeutic efficacy in prostate cancer tumor-bearing mouse models.  
Acknowledgements 
RK is a Marie Curie fellow. Funding from the EU FP7-ITN Marie-Curie Network 
programme RADDEL (290023) is acknowledged.  
  
18 
 
Figure captions 
 
Figure 1. Cell size and granularity of PC3 prostate cancer cells, after intracellular 
uptake of doxorubicin (DOX), empty NC (NC), curcumin-loaded NC (CURC NC) or 
their combinations. Changes in cell size (FSC detector) and granularity (SSC detector) were 
assessed after 4 h of incubation by flow cytometry. The combination of DOX and CURC NC 
but not any of the individual treatments lead to reduction in cell size, reflecting enhanced 
overall cytotoxicity of the combinatory treatment.   
 
Figure 2. Intracellular uptake of CURC NC, in presence or absence of DOX, in PC3 
human prostate cancer cells in vitro. (A) Cellular uptake of DOX (red fluorescence) and 
CURC NC (green fluorescence) was assessed by fluorescence microscopy after 4 h of 
incubation. Nuclei were counterstained with DAPI (blue). The scale bar corresponds to 25 
µm. (B) Dot plots showing PC3 cells after 4 h of incubation with the different treatments. 
Histograms display the fluorescence signals detected from each cell population. Cells treated 
with CURC NC or DOX show individual cell population; with low and high FL2 intensity 
signals, indicative of CURC and DOX uptake, respectively. Cells treated with the 
combinatory treatment show two overlapping populations; cells in population 1 are larger in 
size and are positive for DOX signals (high FL2 intensity). Cells in population 2 are smaller 
in size, reflecting cytotoxicity, and are positive for CURC signals (low FL2 intensity).  
 
Figure 3. Quantification of the intracellular uptake of CURC NCs in PC3 human 
prostate cancer cells in vitro by HPLC-FLd. Cells were quantified for intracellular CURC 
content following 4 h or 6 h of incubation by HPLC-FLd, using a C18 column, 
excitation/emission wavelengths of 345/530 nm and 0.1% TFA in H2O: acetonitrile mobile 
phase.  
 
Figure 4. Cytotoxicity studies of CURC NC, in presence or absence of DOX, in PC3 
human prostate cancer cells in vitro. (A) Microscopic examination of PC3 cells after 
treatment with DOX, CURC NC or combinatory treatment, for 24 h. Cell rounding and 
reduction in cell number was observed for cells treated with the combinatory treatment. The 
scale bar corresponds to 50 µm. (B) PC3 cells were incubated with DOX (0.1 or 1 µM), 
CURC NC (20, 40 or 60 µM) or the combinations for 72 h. Cell viability was determined by 
MTT assay. Values are expressed as mean ± SD (n = 3). * P < 0.05, ** P < 0.01, *** P < 
0.001 (one-way ANOVA test). Asterisks correspond to statistically significant differences 
between particular groups. 
 
Figure 5. Percentage SubG1 cell population in PC3 human prostate cancer cells 
following combinatory treatments in vitro. (A) Representative histograms of SubG1 
quantification in PC3 cells incubated with DOX, CURC, CURC NC or the combinatory 
treatments, following 24 h treatment. (B) Percentage SubG1 quantification in PC3 (top) and 
DU145 cells (bottom) after 24 h treatment. SubG1 was quantified by using PI staining 
method. The combinatory treatment significantly increased the % of SubG1, compared to 
individual DOX or CURC treatments. Values are expressed as mean ± SD (n = 3). 
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